CZMWF (Carl Zeiss Meditec AG) Cyclically Adjusted Revenue per Share: $25.95 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CZMWF Carl Zeiss Meditec AG CZMWF
68 GF Score
Price $33.50
GF Value $82.07
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share?

Carl Zeiss Meditec AG CZMWF -0.30% 68 Cyclically Adjusted Revenue per Share is $25.95 as of Dec. 2025. GuruFocus rates CZMWF with a GF Score™ of 68/100 and a GF Value™ of $82.07 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Carl Zeiss Meditec AG's adjusted revenue per share for the three months ended in Dec. 2025 was $6.696. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $25.95 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Carl Zeiss Meditec AG's average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Carl Zeiss Meditec AG was 11.40% per year. The lowest was 5.30% per year. And the median was 8.65% per year.

As of today (2026-07-17), Carl Zeiss Meditec AG's current stock price is $33.50. Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was $25.95. Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio of today is 1.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.27.


Carl Zeiss Meditec AG  (OTCPK:CZMWF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=33.50/25.95
=1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.27.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Related Terms


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.61 15.97 19.69 17.65 24.89

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.20 23.17 24.49 24.89 25.95

CZMWF vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio falls into.


CZMWF
68GF Score
Carl Zeiss Meditec AG CZMWF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Carl Zeiss Meditec AG's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=6.696/129.3606*129.3606
=6.696

Current CPI (Dec. 2025) = 129.3606.

Carl Zeiss Meditec AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 3.791 100.017 4.903
201606 3.514 100.717 4.513
201609 4.056 101.017 5.194
201612 3.632 101.217 4.642
201703 4.025 101.417 5.134
201706 3.506 102.117 4.441
201709 4.303 102.717 5.419
201712 3.916 102.617 4.937
201803 4.422 102.917 5.558
201806 4.095 104.017 5.093
201809 4.562 104.718 5.636
201812 4.105 104.217 5.095
201903 4.359 104.217 5.411
201906 4.571 105.718 5.593
201909 5.284 106.018 6.447
201912 4.552 105.818 5.565
202003 4.257 105.718 5.209
202006 3.180 106.618 3.858
202009 4.911 105.818 6.004
202012 5.040 105.518 6.179
202103 5.328 107.518 6.410
202106 5.880 108.486 7.011
202109 5.876 109.435 6.946
202112 5.136 110.384 6.019
202203 5.459 113.968 6.196
202206 5.650 115.760 6.314
202209 6.289 118.818 6.847
202212 5.568 119.345 6.035
202303 6.008 122.402 6.350
202306 6.487 123.140 6.815
202309 6.956 124.195 7.245
202312 5.817 123.773 6.080
202403 5.742 125.038 5.940
202406 6.470 125.882 6.649
202409 7.376 126.198 7.561
202412 5.889 127.041 5.997
202503 6.945 127.779 7.031
202506 7.156 128.412 7.209
202509 8.446 129.255 8.453
202512 6.696 129.361 6.696

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $25.95 mean?
Carl Zeiss Meditec AG (CZMWF) has a Cyclically Adjusted Revenue per Share of $25.95 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share too high?
Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is $25.95. Overall, Carl Zeiss Meditec AG has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share of $25.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is $25.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (CZMWF) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.07, compared to a current price of $33.50 — trading 59.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $25.95. Carl Zeiss Meditec AG's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Carl Zeiss Meditec AG (CZMWF), the current Cyclically Adjusted Revenue per Share is $25.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (CZMWF) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of $33.50 is trading 59.2% below its estimated GF Value™ of $82.07. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for CZMWF:

  • Cyclically Adjusted Revenue per Share: $25.95
  • GF Value™: $82.07 vs. price of $33.50 (59.2% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the CZMWF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
68GF Score

Get the complete analysis for CZMWF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.50
Price
$82.07
GF Value